You are here

Pfizer News & MediaPharmaceutical News Intended for Media Professionals

Welcome to Pfizer’s news section — designed to give you access to timely and relevant information about our company. In this section you will find information and resources for journalists, including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.

 

 
February 28, 2017 - FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review EMD Serono's Biologics License Application (BLA) for avelumab* as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 27, 2017, for avelumab in this indication.

 
February 24, 2017 - Pfizer Prices $1,065,000,000 Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of $1,065,000,000 aggregate principal amount of 4.20% notes due 2047. This offering is expected to besold to professional institutional investors in Taiwan, with application to be made to list the notes on the Taipei Exchange.

Pfizer intends to use the net offering proceeds for general corporate purposes, including to repay a portion of its outstanding commercial paper.

The closing of the offering is expected to occur on March 17, 2017, subject to satisfaction of customary closing conditions.

 
February 23, 2017 - Ronald E. Blaylock Elected to Pfizer’s Board of Directors

Pfizer Inc. today announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

 
February 21, 2017 - Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration

Pfizer Inc. (NYSE:PFE) today announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

 
February 16, 2017 - Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)

Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint. There were three comparisons,which found:

Teleconference: Prevenar 13

Pfizer signs long-term agreement to supply Prevenar 13 to world's poorest countries.

Investor Presentations

Access the Pfizer Presentation Archive to view Executive Leadership presentations to shareholders, analysts, and global health care conferences.

Executive Speeches & Commentary

View Executive Leadership speeches on a variety of topics.

 

 

 

Follow us
Pfizer Twitter Community

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

Pfizer Annual Report

Current Stock Price

.
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.